- Home
- ROIV vs RLI Comparison
ROIV vs RLI Comparison
Compare ROIV & RLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- RLI
- Stock Information
- Founded
- ROIV 2014
- RLI 1965
- Country
- ROIV United Kingdom
- RLI United States
- Employees
- ROIV N/A
- RLI N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- RLI Property-Casualty Insurers
- Sector
- ROIV Health Care
- RLI Finance
- Exchange
- ROIV Nasdaq
- RLI Nasdaq
- Market Cap
- ROIV 8.4B
- RLI 7.1B
- IPO Year
- ROIV N/A
- RLI 1985
- Fundamental
- Price
- ROIV $10.76
- RLI $74.35
- Analyst Decision
- ROIV Buy
- RLI Hold
- Analyst Count
- ROIV 4
- RLI 8
- Target Price
- ROIV $17.50
- RLI $78.60
- AVG Volume (30 Days)
- ROIV 5.9M
- RLI 389.2K
- Earning Date
- ROIV 05-29-2025
- RLI 04-23-2025
- Dividend Yield
- ROIV N/A
- RLI 6.74%
- EPS Growth
- ROIV N/A
- RLI N/A
- EPS
- ROIV N/A
- RLI 3.03
- Revenue
- ROIV $122,585,000.00
- RLI $1,733,218,000.00
- Revenue This Year
- ROIV N/A
- RLI N/A
- Revenue Next Year
- ROIV N/A
- RLI $4.70
- P/E Ratio
- ROIV N/A
- RLI $24.58
- Revenue Growth
- ROIV 140.04
- RLI 8.88
- 52 Week Low
- ROIV $8.73
- RLI $68.50
- 52 Week High
- ROIV $13.06
- RLI $91.15
- Technical
- Relative Strength Index (RSI)
- ROIV 49.33
- RLI 45.53
- Support Level
- ROIV $10.58
- RLI $73.74
- Resistance Level
- ROIV $11.77
- RLI $75.22
- Average True Range (ATR)
- ROIV 0.34
- RLI 1.51
- MACD
- ROIV -0.05
- RLI 0.03
- Stochastic Oscillator
- ROIV 15.13
- RLI 41.27
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About RLI RLI Corp. (DE)
RLI Corp underwrites property and casualty insurance through its subsidiaries. The company offers insurance coverage in the specialty admitted market, where the products are designed for special risks. It also offers products in the excess and surplus markets, which provides an alternative for customers with risks or loss exposures that generally cannot be written in the standard admitted market. RLI distributes property and casualty insurance through its wholly-owned branch offices that market to wholesale and retail producers. The company's insurance operation segments include Casualty, Property, and Surety and it derives a majority of its revenue from the Casualty segment.